Betamethasone valerate foam - Stiefel Laboratories

Drug Profile

Betamethasone valerate foam - Stiefel Laboratories

Alternative Names: 0.12% betamethasone 17-α-valerate; 0.12% betamethasone valerate - Stiefel; Betamousse; Luxiq

Latest Information Update: 23 Jul 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Soltec Research; Stiefel Laboratories
  • Developer Mipharm; Stiefel Laboratories
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Fluorinated steroids; Glucocorticoids; Small molecules
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Atopic dermatitis; Psoriasis; Seborrhoeic dermatitis; Skin disorders

Most Recent Events

  • 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
  • 28 Dec 2006 Connetics Corporation has been acquired and merged into Stiefel Laboratories
  • 22 Oct 2004 Celltech Pharmaceuticals has terminated its UK co-promotion rights for Luxiq® effective 31 March 2005
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top